Page last updated: 2024-09-04

resiquimod and Allergy, Drug

resiquimod has been researched along with Allergy, Drug in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Annunziato, F; Brugnolo, F; Campi, P; Cosmi, L; Liotta, F; Maggi, E; Manuelli, C; Parronchi, P; Romagnani, S; Sampognaro, S	1

Other Studies

1 other study(ies) available for resiquimod and Allergy, Drug

Article	Year
The novel synthetic immune response modifier R-848 (Resiquimod) shifts human allergen-specific CD4+ TH2 lymphocytes into IFN-gamma-producing cells. The Journal of allergy and clinical immunology, 2003, Volume: 111, Issue:2 Topics: Adjuvants, Immunologic; Adult; Allergens; Ampicillin; Animals; Antigens, Dermatophagoides; Arthropod Proteins; Cell Line; Cysteine Endopeptidases; Cytokines; Drug Hypersensitivity; Humans; Hypersensitivity, Immediate; Imidazoles; In Vitro Techniques; Interferon-gamma; Models, Immunological; T-Lymphocyte Subsets; Th1 Cells; Th2 Cells	2003

Article

Year

The novel synthetic immune response modifier R-848 (Resiquimod) shifts human allergen-specific CD4+ TH2 lymphocytes into IFN-gamma-producing cells.

The Journal of allergy and clinical immunology, 2003, Volume: 111, Issue:2

Topics: Adjuvants, Immunologic; Adult; Allergens; Ampicillin; Animals; Antigens, Dermatophagoides; Arthropod Proteins; Cell Line; Cysteine Endopeptidases; Cytokines; Drug Hypersensitivity; Humans; Hypersensitivity, Immediate; Imidazoles; In Vitro Techniques; Interferon-gamma; Models, Immunological; T-Lymphocyte Subsets; Th1 Cells; Th2 Cells

2003